menu
    • menu
    [{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Humanized IgG2 Agonistic Monoclonal Antibody","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Toripalimab","moa":"CD40","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eucure Biopharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Eucure Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"YH001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Eucure Biopharma \/ Biocytogen","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Biocytogen"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Syncromune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"YH002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ Syncromune","highestDevelopmentStatusID":"6","companyTruncated":"Eucure Biopharma \/ Syncromune"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Toripalimab","moa":"IgG2","graph1":"Oncology","graph2":"Phase II","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eucure Biopharma \/ ISU ABXIS","highestDevelopmentStatusID":"8","companyTruncated":"Eucure Biopharma \/ ISU ABXIS"},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"ISU ABXIS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Tri-specific Antibody","moa":"CD40","graph1":"Oncology","graph2":"Discovery","graph3":"Eucure Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ ISU ABXIS Co.","highestDevelopmentStatusID":"2","companyTruncated":"Eucure Biopharma \/ ISU ABXIS Co."},{"orgOrder":0,"company":"Eucure Biopharma","sponsor":"Chipscreen NewWay Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"YH008","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eucure Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Eucure Biopharma \/ Chipscreen NewWay Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Eucure Biopharma \/ Chipscreen NewWay Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Eucure Biopharma

    Menu

    Eucure Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH008

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Chipscreen NewWay Biosciences

                            Deal Size : $85.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay ...

                            Details : Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China. YH008 is Biocytogen’s independently developed proprietary bispecific antibody for tumor immunotherapy that exerts antagonistic and agonistic acti...

                            Brand Name : YH008

                            Molecule Type : Large molecule

                            Upfront Cash : $5.7 million

                            February 27, 2023

                            Lead Product(s) : YH008

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Chipscreen NewWay Biosciences

                            Deal Size : $85.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tri-specific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : ISU ABXIS

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-s...

                            Details : YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single agent or in combination with anti-PD-1 monoclonal antibody drugs, YH003 demonstrated strong anti-tumor effects against multiple tumor.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 01, 2022

                            Lead Product(s) : Tri-specific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : ISU ABXIS

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : ISU ABXIS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-...

                            Details : Under the terms of the agreement, ISU ABXIS will utilize the sequence of YH003, Biocytogen’s humanized agonistic anti-CD40 antibody currently in phase II clinical trials, to construct a few groups of tri-specific antibodies and develop cancer drugs for...

                            Brand Name : YH003

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 31, 2022

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : ISU ABXIS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Syncromune

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody (YH002) and Multiple Acti...

                            Details : Under the terms of the agreement, Syncromune will acquire exclusive worldwide rights for development and commercialization of the intratumoral combination therapy containing Eucure’s YH002, and multiple other active ingredients as part of the Syncrovax...

                            Brand Name : YH002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 17, 2022

                            Lead Product(s) : YH002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Syncromune

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH002,YH001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Biocytogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clini...

                            Details : Combination of YH002, a recombinant anti-OX40 humanized IgG1 antibody and YH001, an anti-CTLA-4 monoclonal antibody has shown very good antitumor activity, in invivo efficacy screening platform in patients with advanced solid tumors.

                            Brand Name : YH002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : YH002,YH001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Biocytogen

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocytogen/Eucure Biopharma's CTLA-4 and CD40 mAbs Approved for Phase II Clinical Trials by the FDA

                            Details : A phase II, open-label, multi-center study will evaluate the safety and efficacy of YH003 combined with Toripalimab for the treatment of PD-1-resistant unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).

                            Brand Name : YH003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 06, 2021

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeti...

                            Details : The first trial is designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor efficacy of YH003 combined with Toripalimab (Tuoyi®; an anti-PD-1 mAb) in subjects with advanced solid tumors.

                            Brand Name : YH003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2021

                            Lead Product(s) : YH003,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eucure Biopharma

                            China arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Humanized IgG2 Agonistic Monoclonal Antibody,Toripalimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eucure Biopharma to Present Findings From Anti-CD40 and Anti-CTLA-4 mAb Clinical Trials at the 2021 ASCO Meeti...

                            Details : Preclinical studies demonstrated that YH003 promotes antigen-presenting cell activation and infiltration of effector T cells into tumors.

                            Brand Name : YH003

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 01, 2021

                            Lead Product(s) : Humanized IgG2 Agonistic Monoclonal Antibody,Toripalimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth